Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Authors: Samples, Laura ^{1, 2, ∗∗}, Sadrzadeh, Hossein ³, Frigault, Matthew J. ⁴, Jacobson, Caron A. ⁵, Hamadani, Mehdi ⁶, Gurumurthi, Ashwath ⁷, Strati, Paolo ⁷, Shouval, Roni ⁸, Noy, Ariela ⁸, Riedell, Peter A. ⁹, Dahiya, Saurabh ¹⁰, Maloney, David G. ^{1, 2}, Till, Brian G. ^{1, 2}, Hirayama, Alexandre V. ^{1, 2}, Guathier, Jordan ^{1, 2}, Gopal, Ajay K. ^{1, 2}, Smith, Stephen D. ^{1, 2}, Poh, Christina ^{1, 2}, Lynch, Ryan ^{1, 2}, Ujjani, Chaitra ^{1, 2}, Di, Mengyang ^{1, 2}, Raghunathan, Vikram ^{1, 2}, Shakib-Azar, Mehrdad ¹, Naresh, Kikkeri N. ^{1, 2}, Gooley, Ted A. ¹, Yared, Jean ¹¹, Jain, Michael D. ¹², Locke, Frederick L. ¹², Leslie, Lori Ann ¹³, Epperla, Narendranath ¹⁴, Ghosh, Monalisa ¹⁵, Skarbnik, Alan ¹⁶, Hill, Brian T. ¹⁷, Kamdar, Manali K. ¹⁸, Ortiz-Maldonado, Valentin ¹⁹, Martinez-Cibrian, Nuria ¹⁹, Shune, Leyla ²⁰, Shadman, Mazyar ^{1, 2, ∗}

Source: In Blood January 2025

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

Authors: Locke, Frederick L. ^{1, ∗}, Siddiqi, Tanya ², Jacobson, Caron A. ³, Nikiforow, Sarah ³, Ahmed, Sairah ⁴, Miklos, David B. ⁵, Lin, Yi ⁶, Lunning, Matthew A. ⁷, Hill, Brian T. ⁸, Ghobadi, Armin ⁹, Hu, Zhen-Huan ¹⁰, Hemmer, Michael T. ¹⁰, Zoratti, Michael J. ¹¹, Vunnum, Suresh ¹⁰, Tsang, Jonathan ¹⁰, Spooner, Clare ¹⁰, Smith, Harry ¹⁰, Fu, Christine ¹⁰, Patel, Anik ¹⁰, Miao, Harry ¹⁰, Shahani, Shilpa A. ¹⁰, Mirjah, Debbie L. ¹⁰, Xu, Hairong ¹⁰, Pasquini, Marcelo C. ¹²

Source: In Blood Advances December 2024

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Authors: Jain, Michael D., Jacobs, Miriam T., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R., Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C, Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David, Neelapu, Sattva S., Locke, Frederick L., Ghobadi, Armin

Source: In Blood Advances 27 February 2024 8(4):1042-1050

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Authors: Hill, Brian T., Ma, Shuo, Zent, Clive S., Baran, Andrea M., Wallace, Danielle S., Advani, Anjali, Winter, Allison, Winter, Jane, Gordan, Leo, Karmali, Reem, Liesveld, Jane L., Mulford, Deborah A., Rowland, Chris, Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Barr, Paul M.

Source: In Blood Advances 23 January 2024 8(2):378-387

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Authors: Shadman, Mazyar, Manzoor, Beenish S., Sail, Kavita, Tuncer, Hande H., Allan, John N., Ujjani, Chaitra, Emechebe, Nnadozie, Kamalakar, Rajesh, Coombs, Catherine C., Leslie, Lori, Barr, Paul M., Brown, Jennifer R., Eyre, Toby A., Rampotas, Alexandros, Schuh, Anna, Lamanna, Nicole, Skarbnik, Alan, Roeker, Lindsey E., Bannerji, Rajat, Eichhorst, Barbara, Fleury, Isabelle, Davids, Matthew S., Alhasani, Hasan, Jiang, Dingfeng, Hill, Brian T., Schuster, Stephen J., Brander, Danielle M., Pivneva, Irina, Burne, Rebecca, Guerin, Annie, Mato, Anthony R.

Source: Clinical lymphoma, myeloma & leukemia. 23(7):515-526

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193422989.0x000001&indx=1&recIds=ETOCvdc_100193422989.0x000001

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Authors: Wallace, Danielle S., Rowland, Chris, Hill, Brian T., Baran, Andrea M., Casulo, Carla, Reagan, Patrick M., Winter, Allison, Karmali, Reem, Winter, Jane N., Gordon, Leo I., Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Ma, Shuo, Barr, Paul M.

Source: Leukemia & lymphoma. 64(9):1579-1582

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191127797.0x000001&indx=1&recIds=ETOCvdc_100191127797.0x000001

Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP

Authors: Nichols, Meredith M., Ondrejka, Sarah L., Patil, Sujata, Durkin, Lisa, Hill, Brian T., Hsi, Eric D.

Source: Leukemia & lymphoma. 64(8):1433-1441

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190064229.0x000001&indx=1&recIds=ETOCvdc_100190064229.0x000001

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma

Authors: Cortese, Matthew J., Wei, Wei, Cerdeña, Sebastian, Watkins, Marcus P., Olson, Marissa, Jodon, Gray, Kaiser, Jeff, Haverkos, Bradley, Hughes, Mitchell E., Namoglu, Esin, Grover, Natalie S., Snow, Anson, Orellana-Noia, Victor, Rainey, Magdalena, Sohail, Mohammad, Rudoni, Joslyn, Portell, Craig, Voorhees, Timothy, Landsburg, Daniel J., Kamdar, Manali, Kahl, Brad S., Hill, Brian T.

Source: Leukemia & lymphoma. 64(1):107-118

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100178760291.0x000001&indx=1&recIds=ETOCvdc_100178760291.0x000001

Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

Authors: Hess, Brian T., Giri, Anshu, Park, Yeonhee, Patel, Krina K., Link, Brian K., Nowakowski, Grzegorz S., Maliske, Seth M., Fortin, Sonia, Chavez, Julio C., Saeed, Hayder, Hill, Brian T., Mejia Garcia, Alex V., Maddocks, Kami J., Hanel, Walter, Wagner‐Johnston, Nina D., Messmer, Marcus R., Kahl, Brad S., Watkins, Marcus, Alderuccio, Juan Pablo, Lossos, Izidore S., Nathan, Sunita, Orellana‐Noia, Victor M., Portell, Craig A., Landsburg, Daniel J., Ayers, Emily C., Castillo, Jorge J.

Source: American journal of hematology. 98(2):300-308

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100170803971.0x000001&indx=1&recIds=ETOCvdc_100170803971.0x000001

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Authors: Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., Barta, Stefan K.

Source: In Blood Advances 26 December 2023 7(24):7393-7401

Lenalidomide, rituximab (R²), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.

Authors: Hill, Brian T.¹ (AUTHOR) hillb2@ccf.org, Chen, Yanwen² (AUTHOR), Jagadeesh, Deepa¹ (AUTHOR), Dean, Robert¹ (AUTHOR), Koc, Omer¹ (AUTHOR), Boughan, Kirsten³ (AUTHOR), Cooper, Brenda³ (AUTHOR), Pohlman, Brad¹ (AUTHOR), Caimi, Paolo¹ (AUTHOR), Smith, Mitchell R.^1,4 (AUTHOR)

Source: Leukemia & Lymphoma. Jun2024, Vol. 65 Issue 6, p768-773. 6p.

Subject Terms: *NON-Hodgkin's lymphoma, *LENALIDOMIDE, *PROGRESSION-free survival, *RITUXIMAB, *ADVERSE health care events, *JOINT pain

Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy

Authors: Jalota, Akansha, Hershberger, Courtney E., Patel, Manishkumar S., Mian, Agrima, Faruqi, Aiman, Khademi, Gholamreza, Rotroff, Daniel M., Hill, Brian T., Gupta, Neetu ^∗

Source: In Blood Advances 12 September 2023 7(17):4690-4700

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Authors: Major, Ajay, Yu, Jovian, Shukla, Navika, Che, Yan, Karrison, Theodore G., Treitman, Rachel, Kamdar, Manali K., Haverkos, Bradley M., Godfrey, James, Babcook, Melissa A., Voorhees, Timothy J., Carlson, Sophie, Gaut, Daria, Oliai, Caspian, Romancik, Jason T., Winter, Allison M., Hill, Brian T., Bansal, Radhika, Villasboas Bisneto, Jose C., Nizamuddin, Imran A., Karmali, Reem, Fitzgerald, Lindsey A., Stephens, Deborah M., Pophali, Priyanka A., Trabolsi, Asaad, Schatz, Jonathan H., Hu, Marie, Bachanova, Veronika, Slade, Michael J., Singh, Nathan, Ahmed, Nausheen, McGuirk, Joseph P., Bishop, Michael R., Riedell, Peter A., Kline, Justin

Source: In Blood Advances 22 August 2023 7(16):4528-4538

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Authors: Shouse, Geoffrey, Kaempf, Andy, Gordon, Max J., Artz, Andy, Yashar, David, Sigmund, Audrey M., Smilnak, Gordon, Bair, Steven M., Mian, Agrima, Fitzgerald, Lindsey A., Bajwa, Amneet, Jaglowski, Samantha, Bailey, Neil, Shadman, Mazyar, Patel, Krish, Stephens, Deborah M., Kamdar, Manali, Hill, Brian T., Gauthier, Jordan, Karmali, Reem, Nastoupil, Loretta J., Kittai, Adam S., Danilov, Alexey V.

Source: In Blood Advances 25 July 2023 7(14):3516-3529

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Authors: Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., Cohen, Jonathon B.

Source: In Blood Advances 11 July 2023 7(13):2983-2993

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Authors: Epperla, Narendranath ^∗, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., Cohen, Jonathon B.

Source: In Blood Advances 13 June 2023 7(11):2287-2296

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Authors: Neelapu, Sattva S., Jacobson, Caron A., Ghobadi, Armin, Miklos, David B., Lekakis, Lazaros J., Oluwole, Olalekan O., Lin, Yi, Braunschweig, Ira, Hill, Brian T., Timmerman, John M., Deol, Abhinav, Reagan, Patrick M., Stiff, Patrick, Flinn, Ian W., Farooq, Umar, Goy, Andre H., McSweeney, Peter A., Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C., Herrera, Alex F., Bartlett, Nancy L., Bot, Adrian A., Shen, Rhine R., Dong, Jinghui, Singh, Kanwarjit, Miao, Harry, Kim, Jenny J., Zheng, Yan, Locke, Frederick L.

Source: In Blood 11 May 2023 141(19):2307-2315

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Authors: Jacobs, Miriam T., Jain, Michael D., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick M., Oluwole, Olalekan O., McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison, Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C., Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David B., Neelapu, Sattva S., Ghobadi, Armin, Locke, Frederick L.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22(10):753-759

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

Authors: Hill, Brian T., Ondrejka, Sarah L.

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S54-S56

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196320954.0x000001&indx=1&recIds=ETOCvdc_100196320954.0x000001

The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma

Authors: Sawalha, Yazeed, Radivoyevitch, Tomas, Jia, Xuefei, Tullio, Katherine, Dean, Robert M., Pohlman, Brad, Hill, Brian T., Kalaycio, Matt, Majhail, Navneet S., Jagadeesh, Deepa

Source: Leukemia & lymphoma. 63(2):335-343

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100139847831.0x000001&indx=1&recIds=ETOCvdc_100139847831.0x000001